Dextran and protamine-based solid lipid nanoparticles as potential vectors for the treatment of X-linked juvenile retinoschisis

Human Gene Therapy

Volumn 23, Issue 4, 2011, Pages 345-355

  Delgado, Diego ^a   Del Pozo Rodríguez, Ana ^a   Solinís, Maria Ángeles ^a   Avilés Triqueros, Marcelino ^b   Weber, Bernhard H F ^c   Fernández, Eduardo ^b   Gascón, Alicia R ^a  

^a UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^b MIGUEL HERNÁNDEZ UNIVERSITY   (Spain)

^c UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CLATHRIN; DEXTRAN; DNA; ENHANCED GREEN FLUORESCENT PROTEIN; PROTAMINE; SOLID LIPID NANOPARTICLE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; CORNEA; DRUG ADMINISTRATION ROUTE; DRUG DOSAGE FORM COMPARISON; ENDOCYTOSIS; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; GENE EXPRESSION; GENETIC TRANSFECTION; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NONVIRAL GENE THERAPY; PHOTON CORRELATION SPECTROSCOPY; PIGMENT EPITHELIUM; PLASMID; PROTEIN EXPRESSION; RAT; RETINA DISEASE; RETINOSCHISIS; SUBRETINAL DRUG ADMINISTRATION; X CHROMOSOME LINKED DISORDER;

ANIMALS; DEXTRANS; DNA; DRUG CARRIERS; GENETIC THERAPY; GLYCERIDES; GREEN FLUORESCENT PROTEINS; NANOPARTICLES; PARTICLE SIZE; PROTAMINES; RATS; RETINOSCHISIS; TRANSFECTION;

EID: 84860112894     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2011.115     Document Type: Article

References (34)

1. Abul-Hassan, K., Walmsley, R., and Boulton, M. (2000). Optimization of non-viral gene transfer to human primary retinal pigment epithelial cells. Curr. Eye Res. 20, 361-366. (Pubitemid 30614572)
2. Agarwal, A., Gupta, U., Asthana, A., and Jain, N. K. (2009). Dextran conjugated dendritic nanoconstructs as potential vectors for anti-cancer agent. Biomaterials 30, 3588-3596.
3. Bainbridge, J. W., Smith, A. J., Barker, S. S., et al. (2008). Effect of gene therapy on visual function in Leber's congenital amaurosis. N. Engl. J. Med. 358, 2231-2239. (Pubitemid 351724452)
4. Bejjani, R. A., BenEzra, D., Cohen H., et al. (2005). Nanoparticles for gene delivery to retinal pigment epithelial cells. Mol. Vis. 17, 124-132. (Pubitemid 41358300)
5. Bloquel, C., Bourges, J. L., Touchard, E., et al. (2006). Non-viral ocular gene therapy: Potential ocular therapeutic avenues. Adv. Drug Deliv. Rev. 58, 1224-1242. (Pubitemid 44794428)
6. Colella, P., Cotugno, G., and Auricchio, A. (2009). Ocular gene therapy: Current progress and future prospects. Trends Mol. Med. 15, 23-31.
7. Conley, S. M., and Naash, M. I. (2010). Nanoparticles for retinal gene therapy. Prog. Retin. Eye Res. 29, 376-397.
8. de la Fuente, M., Raviñ a, M., Paolicelli, P., et al. (2010). Chitosanbased nanostructures: A delivery platform for ocular therapeutics. Adv. Drug Deliv. Rev. 62, 100-117.
9. Delgado, D., del Pozo-Rodríguez, A., Solinís, M. A., and Gasco ́ n, A. R. (2011). Understanding the mechanism of protamine in solid lipid nanoparticle-based lipofection: The importance of the entry pathway. Eur. J. Pharm. Biopharm. 79, 495-502.
10. del Pozo-Rodríguez, A., Delgado, D., Solinís, M. A., et al. (2007). Solid lipid nanoparticles: Formulation factors affecting cell transfection capacity. Int. J. Pharm. 339, 261-268.
11. del Pozo-Rodríguez, A., Delgado, D., Solinís, M. A., et al. (2008). Solid lipid nanoparticles for retinal gene therapy: Transfection and intracellular trafficking in RPE cells. Int. J. Pharm. 360, 177-183.
12. del Pozo-Rodriguez, A., Pujals, S., Delgado, D., et al. (2009). A proline-rich peptide improves cell transfection of solid lipid nanoparticles-based non-viral vectors. J. Control. Release 133, 52-59.
13. Finsinger, D., Remy, J. S., Erbacher, P., et al. (2000). Protective copolymer for nonviral gene vectors: Synthesis, vector characterization and application in gene delivery. Gene Ther. 7, 1183-1192. (Pubitemid 30488765)
14. Gascón, A. R., Solinís, M. A., del Pozo-Rodríguez, A., et al. (2011). Lipid nanoparticles for gene therapy. WO2011015701.
15. Hamel, C. (2006). Retinitis pigmentosa. Orphanet J. Rare Dis. 1, 40.
16. Janssen, A., Min, S. H., Molday, L. L., et al. (2008). Effect of latestage therapy on disease progression in AAV-mediated rescue of photoreceptor cells in the retinoschisin-deficient mouse. Mol. Ther. 16, 1010-1017. (Pubitemid 351737064)
17. Jiang, C., Moore, M. J., Zhang, X., et al. (2007). Intravitreal injections of GDNF-loaded biodegradable microspheres are neuroprotective in a rat model of glaucoma. Mol. Vis. 13, 1783-1792. (Pubitemid 47497006)
18. Johnson, E. C., Guo, Y., Cepurna, W. O., and Morrison, J. C. (2009). Neurotrophin roles in retinal ganglion cell survival: Lessons from rat glaucoma models. Exp. Eye Res. 88, 808-815.
19. Klausner, E. A., Peer, D., Chapman, R. L., et al. (2007). Corneal gene therapy. J. Control. Release 124, 107-133. (Pubitemid 350101883)
20. Kumar-Singh, R. (2008). Barriers for retinal gene therapy: Separating fact from fiction. Vision Res. 48, 1671-1680.
21. Liu, X., Brandt, C. R., Rasmussen, C. A., et al. (2007). Ocular drug delivery: Molecules, cells and gene. Can. J. Ophthalmol. 42, 447-454.
22. Maguire, A. M., High, K. A., Auricchio, A., et al. (2009). Agedependent effects of RPE65 gene therapy for Leber's congenital amaurosis: A phase 1 dose-escalation trial. Lancet 374, 1597-1605.
23. Maruyama, K., Iwasaki, F., Takizawa, T., et al. (2004). Novel receptor-mediated gene delivery system comprising plasmid/protamine/sugar- containing polyanion ternary complex. Biomaterials 25, 3267-3273. (Pubitemid 38234787)
24. Min, S. H., Molday, L. L., Seeliger, M. W., et al. (2005). Prolonged recovery of retinal structure/function after gene therapy in an Rs1h-deficient mouse model of X-linked juvenile retinoschisis. Mol. Ther. 12, 644-651 (Pubitemid 41350145)
25. Molday, L. L., Hicks, D., Sauer, C. G., et al. (2001). Expression of X-linked retinoschisis protein RS1 in photoreceptor and bipolar cells. Invest. Ophtalmol. Vis. Sci. 42, 816-825. (Pubitemid 32206926)
26. Mooy, C. M., Van Den Born, L. I., Baarsma, S., et al. (2002). Hereditary X-linked juvenile retinoschisis: A review of the role of Mü ller cells. Arch. Ophthalmol. 120, 979-984. (Pubitemid 34755556)
27. Naik, R., Mukhopadhyay, A., and Ganguli, M. (2009). Gene delivery to the retina: Focus on non-viral approaches. Drug Discov. Today 14, 306-315.
28. Nour, M., Quiambao, A. B., Peterson, W. M., et al. (2003). P2Y2 receptor agonist INS37217 enhances functional recovery after detachment caused by subretinal injection in normal and rds mice. Invest. Ophthalmol. Vis. Sci. 44, 4505-4514. (Pubitemid 37186289)
29. Peeters, L., Sanders, N. N., Braeckmans, K., et al. (2005). Vitreous: A barrier to nonviral ocular gene therapy. Invest. Ophthalmol. Vis. Sci. 46, 3553-3561. (Pubitemid 44264656)
30. Phelan, J. K., and Bok, D. (2000). A brief review of retinitis pigmentosa and the identified retinitis pigmentosa gene. Mol. Vis. 8, 116-124.
31. Provost, N., Le Meur, G., Weber, M., et al. (2005). Biodistribution of rAAV vectors following intraocular administration: Evidence for the presence and persistence of vector DNA in the optic nerve and in the brain. Mol. Ther. 11, 275-283.
32. Sorgi, F. L., Bhattcharya, S., and Huang, L. (1997). Protamine sulfate enhances lipid-mediated gene transfer. Gene Ther. 4, 961-968. (Pubitemid 27437722)
33. Ye, J., Wang, A., Liu, C., et al. (2008). Anionic solid lipid nanoparticles supported on protamine/DNA complexes. Nanotechnology 19, 285708.
34. Zinchuk, V., and Zinchuk, O. (2008). Quantitative colocalization analysis of confocal fluorescence microscopy images. Curr. Protoc. Cell Biol. 39, 4191-41916.